| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $20.0M | — | — |
| R&D Expense | $32.7M | — | +67.2% |
| SG&A Expense | $11.5M | — | +52.6% |
| Operating Income | -$24.2M | — | +10.7% |
| Net Income | -$19.9M | — | +17.5% |
| EPS (Basic) | -$0.42 | — | +38.2% |
| EPS (Diluted) | -$0.42 | — | +38.2% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $78.1M | +48.3% | +35.5% |
| Short-term Investments | $398.7M | -8.9% | +75.1% |
| Accounts Receivable | $58K | — | — |
| Current Assets | $484.7M | -2.8% | +66.6% |
| Total Assets | $497.6M | -2.9% | +64.7% |
| Current Liabilities | $17.9M | -6.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$13.1M | — | +35.5% |
| Capital Expenditures | $86K | — | -70.4% |
| Investing Cash Flow | $37.9M | — | +80.4% |
| Financing Cash Flow | $531K | — | — |
| Free Cash Flow | -$13.1M | — | +36.0% |
| +90.7% |
| Total Liabilities | $26.1M | -6.1% | +60.8% |
| Stockholders' Equity | $471.5M | -2.7% | +65.0% |